POSTED: January 6, 2015

SAN FRANCISCO, January 7, 2015 – - Each year, there are an estimated 800,000 acute ischemic strokes in the United States and more than two million worldwide, causing severe damage to the victim’s brain that often results in disability and even death. What’s troubling is that there is just one primary pharmacologic treatment and only three to five percent of stroke victims receive it because of associated risks.

Zocere, Inc., a New Mexico-based biotech company, believes it has a solution for this global health threat: a biologic-based drug for stroke that has the potential to become the first neuroprotectant on the market. Zocere CEO Wayne Laslie is presenting the drug at the Biotech Showcase 2015 Conference in San Francisco January 12-14 at the Wyndham San Francisco Union Square Hotel.

Co-produced by Demy-Colton Life Science Advisors and EBD Group, Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry’s largest annual healthcare investor conferences. Now in its seventh year, Biotech Showcase is expected to attract upwards of 1,500 attendees.

Zocere’s drug is based on a STEP protein, a cell-permeable, recombinant peptide, that shows promise as a potent brain protecting drug when administered post stroke. It also holds the potential for treating other brain trauma, including concussion. Zocere has exclusive, global rights to the patent-pending technology, and has succeeded in raising a half million dollars. Zocere is seeking capital investment of $1 million to $1.5 million in exchange for equity in the company. These funds will be used to further the Investigational New Drug (IND) enabling studies.

Laslie, a pharmaceutical professional with more than 30 years of experience in pharmaceutical commercialization in U.S. and international markets, believes Zocere’s drug is a transformative technology that the healthcare industry and investors seek. “One doesn’t have to work in health care to know there is a great unmet need in stroke therapeutics. Zocere is working to be the solution.”